High-risk Neuroblastoma in Young Adult and Long Term Survival with Multimodal Therapy: A Case Report

Amaylia Oehadian, Afiati Afiati, Martina Sung, Kevin Yonatan Budiman, Fransisca Fransisca

Abstract


Objective: To present a case of high-risk, stage four neuroblastoma in a 20-year-old woman who survived more than 21 months with the multimodal therapy.

Methods: A case of high-risk, stage four neuroblastoma in a 20-year-old woman who survived more than 21 months with multimodal therapy is reported. The patient initially received neoadjuvant chemotherapy according to the Turkish Pediatric Oncology Group of Neuroblastoma, along with multiple doses of radiotherapy. After two cycles of induction chemotherapy, she successfully underwent tumor debulking surgery.

Results: With the multimodal therapy, patient remains in complete remission state and stable disease of the remaining lesions is observed in this patient.

Conclusions: Neuroblastoma is a rare disease in adults and associated with a high number of mortality. Early and accurate diagnosis and multimodality of treatments are important to achieve disease control. Long term follow up is necessary for such patients.


Keywords


High-risk Neuroblastoma; Long Term Survival; Young Adult.

Full Text:

PDF

References


  1. Aksoylar S, Varan A, Vergin C, Hazar V, Akici F, Dagdemir A, et al. Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group. J Can Res Ther. 2017;13:284–90.
  2. Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S, Araujo DM. Adult versus pediatric neuroblastoma: the MD Anderson cancer center experience. Sarcoma. 2014;2014.
  3. Esiashvili N, Goodman M, Ward K, Marcus Jr RB, Johnstone PA. Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2007;49(1):41–6.
  4. Laverdière C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. JNCI: J National Cancer Institute. 2009;101(16):1131–40.
  5. Zhu J, Wang J, Sun F, Zhen Z, Chen T, Lu S, et al. Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma. . Front Oncol. 2022;12:804310.
  6. Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(4):627–35.
  7. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children’s Oncology Group (COG) study. American Society of Clinical Oncology. J Clin Oncol. 2016:34(Suppl 18):1.
  8. Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D. Children’s Cancer and Leukaemia Group High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–56.
  9. Smith L, Minter S, O’Brien P, Kraveka JM, Medina AM, Lazarchick J. Neuroblastoma in an adult: case presentation and literature review. Annals Clin Laboratory Sci. 2013;43(1):81–4.
  10. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369–86.
  11. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatric Clinics. 2015;62(1):225–56.
  12. Zage PE. Novel therapies for relapsed and refractory neuroblastoma. Children. 2018;5(11):148.




DOI: https://doi.org/10.15850/ijihs.v10n2.2868

Article Metrics

Abstract view : 282 times
PDF - 178 times



 

This Journal indexed by

               

          


Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License



View My Stats